Evidence that high-doseL-arginine may be inappropriate for use by diabetic patients as a prophylactic blocker of methylglyoxal glycation
Authors:
- 1 July 2004
- journal article
- research article
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 11 (5) , 692-696
Abstract
Previous reports have suggested that high-doseL-arginine could be used in diabetic patients as a prophylactic blocker for the initial glycation reaction of proteins by methylglyoxal (MG), a reactive dicarbonyl compound of glucose metabolism. Here, we present several lines of evidence to substantiate that this prophylactic intervention may be inappropriate and should be used with care. First, we demonstrated that when various concentrations ofL-arginine (2.0–8.0 mM) were added to a fixed concentration of MG (1.56 µM) in a buffered lucigenin solution, dose-dependent generation of superoxide anion (O 2 − )-mediated ultraweak chemiluminescence (uwCL) occurs. The suppression of uwCL generation by exogenously added superoxide dismutase further substantiated that the interaction between MG andL-arginine generated O 2 − . This phenomenon can also be demonstrated in a serum-based system. Furthermore, when a fixed concentration ofL-arginine (8.0 mM) was added exogenously to a group of sera obtained from either diabetic patients (n=10) or their matched nondiabetic controls (n=10), a marked discrepancy in the generation of O 2 − -mediated uwCL could be demonstrated (12,534 ± 3,147 vs. 950 ± 350 counts; pL-arginine for prophylactic measures in diabetic patients may be questioned, because the inhibition of the glycation reaction between MG and proteins by high-doseL-arginine unexpectedly produces plethoric O 2 − as a by-product, which may subsequently aggravate the preexisting oxidative stress status of diabetic patients.Keywords
This publication has 20 references indexed in Scilit:
- The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteinsBiochemical Pharmacology, 1994
- Glyoxalase System in Clinical Diabetes Mellitus and Correlation with Diabetic ComplicationsClinical Science, 1994
- The formation of methylglyoxal from triose phosphatesEuropean Journal of Biochemistry, 1993
- The metabolism of aminoacetone to methylglyoxal by semicarbazide-sensitive amine oxidase in human umbilical arteryBiochemical Pharmacology, 1992
- Influence ofL-arginine on glucose mediated collagen cross link precursors in patients with diabetes mellitusAmino Acids, 1991
- Alterations of biochemical and biomechanical properties of rat tail tendons caused by non-enzymatic glycation and their inhibition by dibasic amino acids arginine and lysineDiabetologia, 1991
- Free radical generation by early glycation products: A mechanism for accelerated atherogenesis in diabetesBiochemical and Biophysical Research Communications, 1990
- Stabilization of a reaction intermediate as a catalytic device: definition of the functional role of the flexible loop in triosephosphate isomeraseBiochemistry, 1990
- Aminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-LinkingScience, 1986
- Analysis of methyl glyoxal in foods and beveragesJournal of Agricultural and Food Chemistry, 1985